← Compound index
COMPOUND RECORD / VASOLIN

Vasolin / SlavinormВазолин / Славинорм

Slavinorm is an injectable calf-vessel polypeptide complex studied for vascular disease. The St. Petersburg Institute of Bioregulation and Gerontology developed the experimental preparation described in early animal studies. Vesugen is the defined KED tripeptide.

Source linked

What the studies found

Randomized study in people · 2023

Slavinorm for intermittent claudication: randomized placebo-controlled trial

Pain-free walking distance
Active arms: +46.2% and +31.4%; placebo: +6.5%.
At least 50% walking-distance improvement
28% and 26% in active arms versus 3% with placebo; exact analysis denominators unavailable.
Adverse-event comparison
p=0.59983; event counts absent.

Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.

Study notes · methods, sources and limitations

Participants or model 108 randomized patients; active groups 36/36, placebo groups 18/18

Design Seven-center, double-blind trial with 108 randomized participants. The two Slavinorm groups (36 each) received 5 mg intramuscularly twice or three times weekly for 10 injections. The two placebo groups (18 each) followed the matching schedules.

Important limitations

  • The abstract does not resolve analysis populations, placebo pooling, allocation concealment or missing data. No exact primary-outcome p value or confidence interval is supplied. A nonsignificant adverse-event comparison does not establish safety equivalence.
  • The abstract reports one placebo result across two placebo arms and provides no pooling method. Follow-up lasted up to 91 days. Long-term walking outcomes and detailed adverse-event counts are unavailable in the abstract.

Angiology and Vascular Surgery. 29(1):23–33 · Original clinical journal publication

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2025

Slavinorm in peripheral arterial atherosclerosis: 78-patient comparison

Ankle–brachial index
Both groups: 0.7→0.8 at two months; at three months active remained 0.8, comparator fell to 0.7.
Walking distance in active group
22/38 gained 35–40 m; 4/38 unchanged. The paper prints the range for the remaining 12 participants in reverse order.
Harms
Authors report no adverse reactions; ascertainment and longer follow-up remain unresolved.

At three months the ankle–brachial index was 0.8 with Slavinorm and 0.7 with pentoxifylline. In the Slavinorm group, 22 of 38 participants walked 35–40 m farther.

Study notes · methods, sources and limitations

Participants or model 78 patients: 38 Slavinorm plus baseline care, 40 comparator; diabetes excluded

Design 78 patients without diabetes: 38 received Slavinorm (5 mg intramuscularly, twice weekly for five weeks) plus baseline care, and 40 received pentoxifylline plus baseline care. The paper leaves randomization and masking unspecified.

Important limitations

  • Randomization and masking are not established. Comparator percentages do not consistently translate into integer counts out of 40. Short-term surrogate and walking outcomes do not establish fewer amputations or cardiovascular events.
  • The quoted p values in the paper are not all between-arm tests. The comparison does not establish a general vascular or longevity benefit.

Cardiology and Cardiovascular Surgery. 18(1):102–108 · Original clinical journal publication

Original source or citation ↗

Study results and tables ↗

Randomized study in people · 2026

Vascular polypeptides plus troxerutin in chronic venous disease: randomized trial

VCSS, visit 4
2.33±1.31 versus 3.24±1.62; reported difference −0.92 points (95% CI −1.34 to −0.50), p<0.001.
CIVIQ-20 improvement ≥5 points, visit 4
93.7% versus 75.8%; p=0.0006.
Serious adverse events
None reported in the abstract; nonserious-event counts unavailable.

The abstract reports lower venous severity with adjunctive polypeptides than placebo.

Study notes · methods, sources and limitations

Participants or model 190 randomized participants, 95 per arm; both arms received troxerutin

Design 190 participants in a double-blind randomized comparison; 95 per arm; troxerutin in both arms. Bovine-vessel polypeptide complex; brand not named in the abstract.

Important limitations

  • Full formulation, participant flow, prespecification and detailed harms require the paper. No serious adverse events reported does not mean no adverse events. This adjunctive venous trial is separate from the arterial trials and does not establish purified KED efficacy.
  • Visit 4 was 30±3 days after treatment ended. The rounded displayed means subtract to −0.91; retain the authors’ −0.92 estimate. The abstract leaves the analysis methods and trade-name identity unclear.

Journal of Venous Disorders / Flebologiya. 20(2):89–96 · Original clinical journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Vasolin / Slavinorm

Names in this research collection

Slavinorm · Vascular polypeptide complex

Research background

This vascular polypeptide profile includes trials of injectable Slavinorm and reports on bovine-vessel extracts. Slavinorm studies measured pain-free walking and recovery after vascular surgery.

More study findings

Comparison in people · 2026

Slavinorm after above-knee femoropopliteal bypass: twelve-month comparison

Ankle–brachial index
Baseline 0.46 / 0.44; twelve months 0.80 / 0.65.
Pain-free walking distance
Baseline 31.5 / 23 m; twelve months 138 / 66 m.
Restenosis as printed
7 (11.6%) versus 15 (50%).

Walking distance and ankle–brachial index were higher in the adjunctive group at twelve months; the abstract contains inconsistent restenosis figures.

Author affiliations · Ryazan State Medical University

More reported outcomes
Bypass thrombosis
1 (3.3%) versus 4 (13.3%).
Study notes · methods, sources and limitations

Participants or model 60 postoperative patients, 30 per arm; Fontaine III–IV disease

Design 60 postoperative patients, 30/30; Slavinorm plus standard care versus standard care.

Important limitations

  • Randomization and masking not established; baseline walking differed and both arms underwent surgery. Seven cases are printed as 11.6%, inconsistent with 30 participants. The odds-ratio narrative also needs reconciliation. No established mortality, amputation or purified-KED benefit.
  • Seven of 30 is 23.3%, so the printed percentage is inconsistent. Reported p<0.001 changes are not verified treatment-by-time effects; no pooled risk estimate calculated.

Angiology and Vascular Surgery. 2026;32(1):28–35. PMID 42289061 · Original clinical journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2025

Vessel polypeptides and vascular markers in rabbits of different ages: 2025 conference abstract

Vascular markers and plaque
Favorable findings reported; no numerical treatment effect extracted.

Vascular-marker and plaque findings were reported in an age-stratified rabbit experiment.

Study notes · methods, sources and limitations

Participants or model 40 rabbits: four groups of ten, each with five young and five older animals

Design 40 rabbits, four groups of ten; five young and five older animals per group. Vessel-derived polypeptides; exact brand not confirmed.

Important limitations

  • Conference-level animal evidence; related 2024 work may share animals. Immunostaining does not demonstrate prostacyclin synthesis or a causal mechanism. No human efficacy or equivalence with purified KED established.
  • Conference evidence; possible overlap with 2024 experiments. Staining signals do not establish a mechanism or human benefit.

Kazakhstan gerontology and geriatrics conference, Astana, 10 October 2025; pp.35–36 · Original conference abstract; not a full journal article

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Review of earlier studies · 2026

Review connects vascular extracts, KED and AEDR experimental research

Study of multiple preparations

Preparations reviewed
Vascular polypeptide preparation, KED and AEDR
Endothelial findings
KED restored elevated ET-1 expression toward normal in reported culturesCultures derived from patients are not a clinical treatment trial
Cardiac findings
AEDR experimental cardioprotection summarizedAnimal experiments; no new human trial

The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model Review of vascular-polypeptide, KED and AEDR experiments in endothelial cultures and animal cardiovascular models.

Important limitations

  • Review of earlier experiments, not independent replication. Vascular extracts, KED and AEDR are different preparations; effects cannot be transferred between them. Exact publication day is not supplied by the index; newly indexed 28 October 2026.

Advances in gerontology = Uspekhi gerontologii 39(4) · Journal publication

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Tissue-derived polypeptide complex
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency · Ryazan State Medical University
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

108-person arterial randomized trial; 190-person venous randomized report; separate 78- and 58-person comparisons; 60-person postoperative follow-up through 12 months

Study methods

Original abstracts and a full HTML comparison; trial methods, formulation and harms still need review

Independent replication

Distinct populations and preparations; independent confirmation and cohort checks remain necessary

Source access

Original society/publisher records; full papers pending for several trials

Safety evidence

Short-term reports; no safety-equivalence or long-term vascular-event conclusion

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The bypass abstract gives a restenosis percentage and odds ratio that need clarification. The arterial and venous reports leave questions about placebo groups, adverse events and preparation identity. The vessel-complex results apply to the preparations studied.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Blood vessels: the molecular link

Vasolin / Slavinorm → Vesugen / KED

KED was detected in vessel complex in the 2020 composition paper. Vesugen is the KED short-peptide entry; the separate KED route preserves sequence-based research navigation.

Clinical evidence and limitations

Original vessel-complex records now include 108-person arterial and 190-person venous randomized trials plus separate comparisons. These do not isolate Vesugen or purified KED.

Some randomized-study abstracts omit the preparation name. A shared peptide sequence does not establish clinical equivalence between complex preparations and purified KED.

Related preparations

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2024 · RU2827088C1 · Slavinorm: critical limb-ischemia methodUse · Walking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.70

Reported findings

Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.

Case 1: walking and ankle–brachial index
Walking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.705 monthsBefore versus after surgery and multidrug care
Case 2: walking and ankle–brachial index
Walking distance reported as 800 m; affected-leg ABI increased from 0.27 to 0.804 monthsBefore versus after combined care
All reported results, comparisons and limitations →

Use. This 2024 method patent includes Slavinorm during combined treatment of critical limb ischemia in diabetes.

The combined-care claim is not a controlled estimate of Slavinorm's independent effect and does not prove equivalence to a synthetic vascular peptide.

Publication
RU2827088C1 ↗ · 2024-09-23
Earliest priority / filing
Not established / 2024-03-20
Original applicant / assignee
Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method for combined treatment of patients with critical ischemia of lower extremities with underlying diabetes mellitus

Inventors: Евгений Петрович Кривощеков; Владислав Павлович Компаниец; Владислав Евгеньевич Романов; Николай Александрович Лысов; Максим Вячеславович Яшков; Дмитрий Валерьевич Роднянский.

RU2827088C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2017

Slavinorm and cortical microcirculation in older hypertensive rats

Cortical microvessel density was about 1.7 times that of untreated hypertensive rats two months after one course. Perfusion rose but remained below that of normotensive rats.

Pial microvessel density · About 1.7 times the untreated hypertensive group and 1.8 times the normotensive group.

Study notes and original source
2017Animal / experimentalFull text available

Slavinorm and cortical microcirculation in older hypertensive rats

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences

Slavinorm, calf-vessel polypeptide complex

Format: Original journal PDF · Reviewed: See scope

I. B. Sokolova, I. V. Sergeev, G. A. Ryzhak, V. Kh. Khavinson, L. S. Kozina · Advances in Gerontology. 30(4):534–537

Cortical microvessel density was about 1.7 times that of untreated hypertensive rats two months after one course. Perfusion rose but remained below that of normotensive rats.

Results and tables

Reported findings and study design

Three groups of 12-month-old male rats: 12 treated SHR, 19 untreated SHR, and 10 normotensive Wistar–Kyoto controls. 0.25 mg per rat intramuscularly, once daily for five days, followed by a two-day break and five more injections. Measurements in the sensorimotor cortex were taken two months after treatment.

Population or model 41 male rats: 12 treated hypertensive, 19 untreated hypertensive, 10 normotensive controls

Results · Original Russian paper, methods and Figures 1–3
MeasureResultComparison, timing and statistics
Pial microvessel densityAbout 1.7 times the untreated hypertensive group and 1.8 times the normotensive group.
Artery and arteriole densityAbout 1.7 times the untreated hypertensive group and 2.3 times the normotensive group.
Cortical perfusion and oxygenationBoth increased versus untreated hypertensive rats. Perfusion stayed below the normotensive group.

The paper names the St. Petersburg Institute of Bioregulation and Gerontology as the developer and lists Pavlov Institute of Physiology as a coauthor affiliation. Animal overlap with the related 2017 paper is unclear.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
41 male rats: 12 treated hypertensive, 19 untreated hypertensive, 10 normotensive controls
Source reviewed
Original methods and results, including Figures 1–3.
Study limitations
  • The methods leave randomization and masking unspecified.
  • The two 2017 publications share investigators and closely related experiments. Animal reuse is unclear.

Reviewed 2026-11-16.

Read the source ↗

Animal research · 2017

Slavinorm and cortical microcirculation after one or two courses in hypertensive rats

After two courses, older rats had about 1.6 times the cortical microvessel density and about 15% higher perfusion than untreated hypertensive rats of the same age.

Pial microvessel density versus age-matched untreated SHR · About 1.2 times as high after one course in younger rats and 1.6 times as high after two courses in older rats.

Study notes and original source
2017Animal / experimentalFull text available

Slavinorm and cortical microcirculation after one or two courses in hypertensive rats

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences

Slavinorm, calf-vessel polypeptide complex

Format: Original journal PDF · Reviewed: See scope

I. B. Sokolova, G. A. Ryzhak, V. Kh. Khavinson · Advances in Gerontology. 30(5):671–675

After two courses, older rats had about 1.6 times the cortical microvessel density and about 15% higher perfusion than untreated hypertensive rats of the same age.

Results and tables

Reported findings and study design

Four SHR groups: 6 untreated and 14 treated at the 6-month assessment, 6 untreated and 14 treated at the 12-month assessment. A normotensive group provided a reference. 0.25 mg per rat intramuscularly, once daily for five days, followed by a two-day break and five more injections. The younger group received one course at 4 months. The older group received courses at 4 and 10 months. Measurements were taken two months after the last course.

Population or model Four groups of hypertensive male rats (6, 14, 6 and 14), with a normotensive reference group

Results · Original Russian paper, group table and Figures 1–3
MeasureResultComparison, timing and statistics
Pial microvessel density versus age-matched untreated SHRAbout 1.2 times as high after one course in younger rats and 1.6 times as high after two courses in older rats.
Perfusion after one course23.8 ± 1.3 versus 25.1 ± 1.1 perfusion units in untreated and treated younger rats, respectively. The difference was statistically nonsignificant.
Perfusion after two coursesAbout 15% above untreated older SHR and below the normotensive reference group.

The authors compared treated and untreated rats at each age. The treatment-course comparison also differs by age, and animal overlap with the related 2017 paper is unclear.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
Four groups of hypertensive male rats (6, 14, 6 and 14), with a normotensive reference group
Source reviewed
Original methods, group table and results for cortical vessel density, perfusion and oxygen saturation.
Study limitations
  • The one- and two-course treatment groups were assessed at different ages.
  • The two 2017 reports may share animals. The studies measured local cortical blood flow in rats.

Reviewed 2026-11-16.

Read the source ↗

Experiment described in a patent · 2024

Slavinorm: critical limb-ischemia method — RU2827088C1

Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.

Case 1: walking and ankle–brachial index · Walking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.70 · Before versus after surgery and multidrug care · 5 months

Study notes and original source
2024Patent / reported experimentsFull text available

Slavinorm: critical limb-ischemia method — RU2827088C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Евгений Петрович Кривощеков, Владислав Павлович Компаниец, Владислав Евгеньевич Романов, Николай Александрович Лысов, Максим Вячеславович Яшков, Дмитрий Валерьевич Роднянский · RU2827088C1 · patent family RU2827088C1

Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.

Results and tables

Reported patent results

Reported findings

Both cases reportedly improved after combined care, but bypass thrombosis or loss of bypass function also occurred during follow-up.

Two illustrative patients with diabetes and critical limb ischemia received bypass surgery, multiple medicines and adjunctive Slavinorm.

Population or model Two illustrative patients with diabetes and critical limb ischemia received bypass surgery, multiple medicines and adjunctive Slavinorm.

Results · Clinical Examples 1 and 2, including later bypass follow-up.
MeasureResultComparison, timing and statistics
Case 1: walking and ankle–brachial indexWalking distance increased from 10 m to 700 m; affected-leg ABI increased from 0.32 to 0.70Before versus after surgery and multidrug care · 5 months
Case 2: walking and ankle–brachial indexWalking distance reported as 800 m; affected-leg ABI increased from 0.27 to 0.80Before versus after combined care · 4 months
Case 2: later deteriorationBypass thrombosis; walking distance fell to 300 m, without reported critical ischemiaEarlier 800 m result was not fully maintained · 1 year

Two uncontrolled cases cannot isolate Slavinorm from surgery or concurrent medicines. The text also contains inconsistent calendar dates. Proposed angiogenesis mechanisms are not independently established.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Two illustrative patients with diabetes and critical limb ischemia received bypass surgery, multiple medicines and adjunctive Slavinorm.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The combined-care claim is not a controlled estimate of Slavinorm's independent effect and does not prove equivalence to a synthetic vascular peptide.
  • Two uncontrolled cases cannot isolate Slavinorm from surgery or concurrent medicines. The text also contains inconsistent calendar dates. Proposed angiogenesis mechanisms are not independently established.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Comparison in people · 2026

Slavinorm after above-knee femoropopliteal bypass: twelve-month comparison

Walking distance and ankle–brachial index were higher in the adjunctive group at twelve months; the abstract contains inconsistent restenosis figures.

Ankle–brachial index · Baseline 0.46 / 0.44; twelve months 0.80 / 0.65.

Study notes and original source
2026Human comparative studyRussian-language source

Slavinorm after above-knee femoropopliteal bypass: twelve-month comparison

Author affiliations · Ryazan State Medical University

Slavinorm bovine-vessel polypeptide complex plus standard care · Original clinical journal publication

Format: Original publisher abstract · Reviewed: Abstract only. Full tables unavailable.

I. A. Suchkov, A. V. Lyasheva, V. O. Povarov, R. E. Kalinin, I. V. Vezenova · Angiology and Vascular Surgery. 2026;32(1):28–35. PMID 42289061

Walking distance and ankle–brachial index were higher in the adjunctive group at twelve months; the abstract contains inconsistent restenosis figures.

Results and tables

Reported findings and study design

60 postoperative patients, 30/30; Slavinorm plus standard care versus standard care.

Population or model 60 postoperative patients, 30 per arm; Fontaine III–IV disease

Results · Complete publisher abstract; full tables pending
MeasureResultComparison, timing and statistics
Ankle–brachial indexBaseline 0.46 / 0.44; twelve months 0.80 / 0.65.
Pain-free walking distanceBaseline 31.5 / 23 m; twelve months 138 / 66 m.
Restenosis as printed7 (11.6%) versus 15 (50%).
Bypass thrombosis1 (3.3%) versus 4 (13.3%).

Seven of 30 is 23.3%, so the printed percentage is inconsistent. Reported p<0.001 changes are not verified treatment-by-time effects; no pooled risk estimate calculated.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
60 postoperative patients, 30 per arm; Fontaine III–IV disease
Source reviewed
Publisher abstract; follow-up at 1, 3, 6, 9 and 12 months.
Study limitations
  • Randomization and masking not established; baseline walking differed and both arms underwent surgery.
  • Seven cases are printed as 11.6%, inconsistent with 30 participants. The odds-ratio narrative also needs reconciliation.
  • No established mortality, amputation or purified-KED benefit.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2025

Vessel polypeptides and vascular markers in rabbits of different ages: 2025 conference abstract

Vascular-marker and plaque findings were reported in an age-stratified rabbit experiment.

Study notes and original source
2025Animal / experimentalRussian-language source

Vessel polypeptides and vascular markers in rabbits of different ages: 2025 conference abstract

Vessel-derived polypeptide preparation; Slavinorm brand not verified · Original conference abstract; not a full journal article

Format: Organizer-hosted proceedings PDF · Reviewed: Selected abstract text, pp. 35–36

A. G. Sopromadze, D. S. Medvedev, N. S. Linkova, A. V. Borodulin, V. O. Polyakova · Kazakhstan gerontology and geriatrics conference, Astana, 10 October 2025; pp.35–36

Vascular-marker and plaque findings were reported in an age-stratified rabbit experiment.

Results and tables

Reported findings and study design

40 rabbits, four groups of ten; five young and five older animals per group. Vessel-derived polypeptides; exact brand not confirmed.

Population or model 40 rabbits: four groups of ten, each with five young and five older animals

Results · Original conference abstract, pp.35–36; text only
MeasureResultComparison, timing and statistics
Vascular markers and plaqueFavorable findings reported; no numerical treatment effect extracted.

Conference evidence; possible overlap with 2024 experiments. Staining signals do not establish a mechanism or human benefit.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
40 rabbits: four groups of ten, each with five young and five older animals
Source reviewed
Original conference abstract, distinct from adjacent narrative reviews; no individual DOI verified.
Study limitations
  • Conference-level animal evidence; related 2024 work may share animals.
  • Immunostaining does not demonstrate prostacyclin synthesis or a causal mechanism.
  • No human efficacy or equivalence with purified KED established.

Reviewed 2026-11-06.

Read the source ↗

Randomized study in people · 2023

Slavinorm for intermittent claudication: randomized placebo-controlled trial

Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.

Study notes and original source
2023Randomized trialRussian-language source

Slavinorm for intermittent claudication: randomized placebo-controlled trial

Slavinorm, bovine-vessel polypeptide complex · Original clinical journal publication

Format: Original society-hosted issue abstracts · Reviewed: Complete original abstract checked; full article pending

I. A. Suchkov, R. E. Kalinin, N. D. Mzhavanadze, A. A. Kamaev, A. G. Burenin, R. N. Larkov · Angiology and Vascular Surgery. 29(1):23–33

Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.

Results and tables

Reported findings and study design

Seven-center, double-blind trial with 108 randomized participants. The two Slavinorm groups (36 each) received 5 mg intramuscularly twice or three times weekly for 10 injections. The two placebo groups (18 each) followed the matching schedules.

Population or model 108 randomized patients; active groups 36/36, placebo groups 18/18

Results · Original journal abstract; no full tables
MeasureResultComparison, timing and statistics
Pain-free walking distanceActive arms: +46.2% and +31.4%; placebo: +6.5%.
At least 50% walking-distance improvement28% and 26% in active arms versus 3% with placebo; exact analysis denominators unavailable.
Adverse-event comparisonp=0.59983; event counts absent.

The abstract reports one placebo result across two placebo arms and provides no pooling method. Follow-up lasted up to 91 days. Long-term walking outcomes and detailed adverse-event counts are unavailable in the abstract.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
108 randomized patients; active groups 36/36, placebo groups 18/18
Source reviewed
Original journal abstract; four-arm design and selected outcomes checked.
Study limitations
  • The abstract does not resolve analysis populations, placebo pooling, allocation concealment or missing data.
  • No exact primary-outcome p value or confidence interval is supplied.
  • A nonsignificant adverse-event comparison does not establish safety equivalence.

Reviewed 2026-11-06.

Read the source ↗

Comparison in people · 2025

Slavinorm in peripheral arterial atherosclerosis: 78-patient comparison

At three months the ankle–brachial index was 0.8 with Slavinorm and 0.7 with pentoxifylline. In the Slavinorm group, 22 of 38 participants walked 35–40 m farther.

Study notes and original source
2025Human comparative studyFull text available

Slavinorm in peripheral arterial atherosclerosis: 78-patient comparison

Slavinorm; comparator received baseline care and pentoxifylline · Original clinical journal publication

Format: Original publisher HTML · Reviewed: Methods and selected results narrative checked

I. I. Katelnitsky, E. S. Katelnitskaya · Cardiology and Cardiovascular Surgery. 18(1):102–108

At three months the ankle–brachial index was 0.8 with Slavinorm and 0.7 with pentoxifylline. In the Slavinorm group, 22 of 38 participants walked 35–40 m farther.

Results and tables

Reported findings and study design

78 patients without diabetes: 38 received Slavinorm (5 mg intramuscularly, twice weekly for five weeks) plus baseline care, and 40 received pentoxifylline plus baseline care. The paper leaves randomization and masking unspecified.

Population or model 78 patients: 38 Slavinorm plus baseline care, 40 comparator; diabetes excluded

Results · Original full HTML; selected outcomes
MeasureResultComparison, timing and statistics
Ankle–brachial indexBoth groups: 0.7→0.8 at two months; at three months active remained 0.8, comparator fell to 0.7.
Walking distance in active group22/38 gained 35–40 m; 4/38 unchanged. The paper prints the range for the remaining 12 participants in reverse order.
HarmsAuthors report no adverse reactions; ascertainment and longer follow-up remain unresolved.

The quoted p values in the paper are not all between-arm tests. The comparison does not establish a general vascular or longevity benefit.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
78 patients: 38 Slavinorm plus baseline care, 40 comparator; diabetes excluded
Source reviewed
Original HTML methods, results and references; no independent reanalysis.
Study limitations
  • Randomization and masking are not established.
  • Comparator percentages do not consistently translate into integer counts out of 40.
  • Short-term surrogate and walking outcomes do not establish fewer amputations or cardiovascular events.

Reviewed 2026-11-06.

Read the source ↗

Randomized study in people · 2026

Vascular polypeptides plus troxerutin in chronic venous disease: randomized trial

The abstract reports lower venous severity with adjunctive polypeptides than placebo.

VCSS, visit 4 · 2.33±1.31 versus 3.24±1.62; reported difference −0.92 points (95% CI −1.34 to −0.50), p<0.001.

Study notes and original source
2026Randomized trialRussian-language source

Vascular polypeptides plus troxerutin in chronic venous disease: randomized trial

Bovine-vessel polypeptide complex; brand not named in the abstract · Original clinical journal publication

Format: Original publisher abstract; full article behind purchase access · Reviewed: Complete original abstract checked

I. A. Suchkov, A. A. Kamaev, A. V. Chupin, S. V. Sapelkin, A. G. Burenin · Journal of Venous Disorders / Flebologiya. 20(2):89–96

The abstract reports lower venous severity with adjunctive polypeptides than placebo.

Results and tables

Reported findings and study design

190 participants in a double-blind randomized comparison; 95 per arm; troxerutin in both arms. Bovine-vessel polypeptide complex; brand not named in the abstract.

Population or model 190 randomized participants, 95 per arm; both arms received troxerutin

Results · Original publisher abstract; full paper not assessed
MeasureResultComparison, timing and statistics
VCSS, visit 42.33±1.31 versus 3.24±1.62; reported difference −0.92 points (95% CI −1.34 to −0.50), p<0.001.
CIVIQ-20 improvement ≥5 points, visit 493.7% versus 75.8%; p=0.0006.
Serious adverse eventsNone reported in the abstract; nonserious-event counts unavailable.

Visit 4 was 30±3 days after treatment ended. The rounded displayed means subtract to −0.91; retain the authors’ −0.92 estimate. The abstract leaves the analysis methods and trade-name identity unclear.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
190 randomized participants, 95 per arm; both arms received troxerutin
Source reviewed
Original abstract; a manufacturer Slavinorm attribution is separate from the unnamed preparation in this abstract.
Study limitations
  • Full formulation, participant flow, prespecification and detailed harms require the paper.
  • No serious adverse events reported does not mean no adverse events.
  • This adjunctive venous trial is separate from the arterial trials and does not establish purified KED efficacy.

Reviewed 2026-11-06.

Read the source ↗

Comparison in people · 2026

Vascular polypeptides during rehabilitation after myocardial infarction with type 2 diabetes

In 58 patients after myocardial infarction, median pain-free walking distance at day 50 was 260 vs 190 m with Slavinorm plus rehabilitation versus rehabilitation alone. Six of 29 Slavinorm recipients had injection-site pain.

Study notes and original source
2026Human comparative studyFull text available

Vascular polypeptides during rehabilitation after myocardial infarction with type 2 diabetes

Slavinorm 5 mg bovine-vessel polypeptide lyophilizate for intramuscular injection. · Original clinical journal publication

Format: Original publisher full text · Reviewed: Methods, selected tables and adverse events checked

M. A. Simonyan, L. A. Marchenkova, V. A. Vasileva · Bulletin of Rehabilitation Medicine. 25(2):8–22

In 58 patients after myocardial infarction, median pain-free walking distance at day 50 was 260 vs 190 m with Slavinorm plus rehabilitation versus rehabilitation alone. Six of 29 Slavinorm recipients had injection-site pain.

Results and tables

Reported findings and study design

Open prospective comparison in 58 patients with type 2 diabetes and leg atherosclerosis after myocardial infarction, 29 per arm. Both arms received rehabilitation.

Population or model 58 patients: 29 adjunctive polypeptides plus rehabilitation, 29 rehabilitation alone; conducted in 2025

Dose, route and schedule

Slavinorm 5 mg intramuscularly twice weekly for five weeks (10 injections). Both groups received cardiometabolic rehabilitation. Assessments were at baseline, day 15 and day 50.

Protocol source ↗ · Original publisher full text, methods, Tables 3–4 and adverse events

Results · Original publisher full text, methods, Tables 3–4 and adverse events
MeasureResultComparison, timing and statistics
Pain-free walking distance · day 50260 vs 190 mSlavinorm plus rehabilitation versus rehabilitation alone. Baseline medians 180 and 175 m. · Table 4 marks p < 0.001 between groups at day 50.
Walking Impairment Questionnaire · day 5065 vs 47 pointsBaseline medians 45 and 44. · Table 4 marks p < 0.001 between groups at day 50.
Timed Up and Go · day 508.5 vs 9.6 secondsBaseline medians 10.0 and 9.8 seconds. · Table 3 marks p < 0.01 between groups at day 50.
Barthel Index · day 50100.0 vs 94.2 pointsBoth arms improved from baseline. The table does not mark a day 50 between-arm difference.
Injection-site pain6/29 (20.7%)The investigators report no serious adverse events, systemic allergic reactions or early discontinuations attributed to the study drug.
Table 4 · walking outcomes
Table 4 · walking outcomes
MeasureTimeSlavinorm + rehabilitationRehabilitation
Pain-free distance (m)Baseline180 [150–220]175 [145–215]
Pain-free distance (m)Day 15210 [180–250]185 [155–225]
Pain-free distance (m)Day 50260 [220–300]190 [160–230]
WIQ scoreBaseline45 [38–52]44 [37–51]
WIQ scoreDay 1555 [48–62]46 [39–53]
WIQ scoreDay 5065 [58–72]47 [40–54]

Median [interquartile interval]. The narrative says control distance stopped increasing after day 15. Table 4 gives 185 m at day 15 and 190 m at day 50. Values here follow the table.

The comparison was open and the allocation method is unclear. These endpoint comparisons concern adjunctive injected Slavinorm during rehabilitation.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
58 patients: 29 adjunctive polypeptides plus rehabilitation, 29 rehabilitation alone; conducted in 2025
Source reviewed
Original publisher full text, methods, Tables 3–4 and adverse events
Study limitations
  • Open prospective comparison. The paper describes two comparable groups and does not document random assignment or concealment.
  • Multiple outcomes were tested in a small short-term study. The published narrative and some table entries disagree. The source page preserves those discrepancies.

Reviewed 2026-11-13.

Read the source ↗

Review of earlier studies · 2026

Peptidergic regulation of age-related alterations in the cardiovascular system

The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.

Study notes and original source
2026ReviewEnglish abstract

Peptidergic regulation of age-related alterations in the cardiovascular system

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

· Journal publication

Ryzhak GA, Popovich IG, Kozina LS, Arutionov VA, Arutjunyan AV · Advances in gerontology = Uspekhi gerontologii 39(4)

The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.

Results and tables

Reported findings and study design

The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.

Population or model Review of vascular-polypeptide, KED and AEDR experiments in endothelial cultures and animal cardiovascular models.

Results · Indexed abstract checked
MeasureResultComparison, timing and statistics
Preparations reviewedVascular polypeptide preparation, KED and AEDR
Endothelial findingsKED restored elevated ET-1 expression toward normal in reported culturesCultures derived from patients are not a clinical treatment trial
Cardiac findingsAEDR experimental cardioprotection summarizedAnimal experiments; no new human trial

Review of earlier experiments, not independent replication. Vascular extracts, KED and AEDR are different preparations; effects cannot be transferred between them. Exact publication day is not supplied by the index; newly indexed 28 October 2026.

Source for these results ↗ · Reviewed 2026-10-31

Population / setting
Review of vascular-polypeptide, KED and AEDR experiments in endothelial cultures and animal cardiovascular models.
Source reviewed
Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
  • Review of earlier experiments, not independent replication. Vascular extracts, KED and AEDR are different preparations; effects cannot be transferred between them. Exact publication day is not supplied by the index; newly indexed 28 October 2026.

Reviewed 2026-10-31.

Read the source ↗

Review of earlier studies · 2019

Polypeptide vessel complex and its role in physiology function regulation in aging pathology

Reviews calf-vessel extract Slavinorm/Vasolin, including lipid metabolism, hemostasis and vessel-wall repair.

Study notes and original source
2019ReviewEnglish abstract

Polypeptide vessel complex and its role in physiology function regulation in aging pathology

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Kuznik BI, Ryzhak GA, Khavinson VK · Adv Gerontol 32(1-2):174-179. PMID 31228385

Reviews calf-vessel extract Slavinorm/Vasolin, including lipid metabolism, hemostasis and vessel-wall repair.

Population / setting
Animal models of vascular and age-associated pathology
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • This record concerns the tissue extract, not isolated KED/Vesugen.
  • Animal findings and a narrative review do not establish human vascular benefit.

Reviewed 2026-09-29.

Read the source ↗

Laboratory analysis · 2020

Identification of short peptides in the composition of polypeptide complexes isolated from animal organs

Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.

Study notes and original source
2020Analytical / composition studyFull text available

Identification of short peptides in the composition of polypeptide complexes isolated from animal organs

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency

I. K. Zhurkovich, N. G. Kovrov, G. A. Ryzhak, E. S. Mironova, V. Kh. Khavinson · Uspekhi Sovremennoi Biologii 140(2):140–148

Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.

Results and tables

Reported findings and study design

UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.

Population or model Animal-organ polypeptide complexes analyzed by UHPLC–MS

Results · Original analytical paper, Table 3 and chromatograms.
MeasureResultComparison, timing and statistics
EDG and AEDL in the bronchial mucosa complexEDG 0.028% and AEDL 0.060% of the analyzed extract
Identified short peptides by extract
Identified short peptides by extract
ExtractSequenceReported proportion
Bronchial mucosaEDG0.028%
Bronchial mucosaAEDL0.060%
VesselsKED0.020%
CartilageAED0.020%
BrainEDR0.024%
PancreasKEDW0.035%

These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
Animal-organ polypeptide complexes analyzed by UHPLC–MS
Source reviewed
Original analytical paper, test method, Table 3 and chromatograms in Figures 1–6.
Study limitations
  • Molecular detection does not prove identical pharmacology or clinical equivalence.
  • The paper’s discussion of clinical work is not an independent clinical trial.

Reviewed 2026-11-15.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗